"id:ID","description","label","studyDesignRationale","bcCategories","name","studyInvestigationalInterventions","id","studyEstimands","documentVersion","uuid"
"820","The main design for the study","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","[]","Study Design 1","[]","StudyDesign_1","[]","","f0427a02-70df-40b8-b334-305375a33212"
